Discover our Portfolio
Pharnext, a biopharmaceutical company created in 2007, is developing new treatments targeting severe neurodegenerative diseases – rare or common – current without satisfactory therapeutic solutions.
Pharnext has developed a new drug paradigm called PLEOTHERAPY ™. The approach is based on a proprietary technological platform that relies on the pharmacology of biological networks. The company identifies and develops synergistic combinations of drugs already approved but for other diseases. These treatments, called PLEODRUG ™, are developed at new, lower optimal doses and under a new galenic formulation. The advantages of PLEODRUG ™ are important: excellent safety profile, simultaneous action on several therapeutic targets, strong and robust intellectual property.